In the latest development of the Zofran (ondansetron) multi-district litigation, GlaxoSmithKline’s request for dismissal of all claims were denied by Judge F. Dennis Saylor IV, the Massachusetts district judge presiding over the litigation. About 200 cases with similar claims were consolidated into the multidistrict litigation, or “MDL,” for the purpose of streamlining pre-trial proceedings and expediting discovery. Women affected by Zofran (ondansetron) claim the drug caused congenital heart defects, cleft palate, and other malformations in their infants, after they were prescribed Zofran (ondansetron) to combat morning sickness. Plaintiffs further allege that GSK marketed the anti-nausea medication “off label,” or for uses unapproved by the FDA, hiding associated risks of the drug.
Plaintiffs’ firm Grant & Eisenhofer (“G&E”) filed the first case in the country and has filed many cases in the MDL. Serving co-lead on the Plaintiffs’ Executive Committee, G&E’s Beth Graham weighed in on the ruling, stating “We are extremely pleased with judge’s decision. We think it’s well-reasoned and we look forward to representing the hundreds of families afflicted by GSK’s conduct.” If you or a loved one took Zofran (ondansetron) for morning sickness during pregnancy and your baby was born with a cleft palate or congenital heart defect, please contact us at 877-978-0169 for a confidential evaluation of your potential claim.